



EV 20961689 US

<b>FORM HDP-1449 (Based on Form PTO-1449)</b>  <b>PATENT AND TRADEMARK OFFICE</b> <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)  Sheet 1 of 1	ATTORNEY DOCKET NO.	SERIAL NO.
	6794S-000019/US	09/897,801
	APPLICANT	
	Pinkerton, Thomas C.	
	FILING DATE	GROUP
June 29, 2001	1615	

Express Mail No. EV 262961689 US

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.	<i>AD</i>	5,983,130	11/09/1999	Phipps et al.	604/20	

FOREIGN PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No
2.	<i>AK</i>	WO 02/02178	01/10/2002	<del>PCT</del> <i>WIPO</i>	A61M 37/00	
3.		WO 02/02179	01/10/2002	<del>PCT</del> <i>WIPO</i>	A61M 37/00	
4.		WO 01/13989	03/01/2001	<del>PCT</del> <i>WIPO</i>	A61N 1/32	
5.		WO 99/64580	12/16/1999	<del>PCT</del> <i>WIPO</i>	E12N 15/00	
6.	<i>AK</i>	WO 99/58188	11/18/1999	<del>PCT</del> <i>WIPO</i>	A61N 1/00	

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
7.	<i>AK</i>	PCT, International Searching Authority; 5/11/2002

RECEIVED  
DEC 06 2002  
TECH CENTER 1600/2900

Examiner: <i>Carol E. [Signature]</i>	Date Considered: <i>4/16/03</i>
---------------------------------------	---------------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

ATTORNEY DOCKET NO.

SERIAL No.

6794S-000019/US

09/897,801

APPLICANT

Pinkerton, Thomas C.

FILING DATE

GROUP

June 29, 2001

1615

## PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 6

## U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.	CA	2,619,962	12/02/1952	Rosenthal	128/253	
2.		3,814,097	06/04/1974	Ganderton, et al.	128/268	
3.		3,964,482	06/22/1976	Gerstel, et al.	128/260	
4.		4,270,537	06/02/1981	Romaine	128/218 A	
5.		4,592,753	06/03/1986	Panoz	604/897	
6.		4,886,499	12/12/1989	Cirelli, et al.	604/131	
7.		5,003,987	04/02/1991	Grinwald	128/734	
8.		5,098,389	03/24/1992	Cappucci	604/158	
9.		5,156,591	10/20/1992	Gross, et al.	604/20	
10.		5,250,023	10/05/1993	Hai Bang Lee, et al.	604/20	
11.		5,279,544	01/18/1994	Gross, et al.	604/20	
12.		5,279,552	01/18/1994	Magnet	604/47	
13.		5,417,662	05/23/1995	Hjertman, et al.	604/117	
14.		5,527,288	06/18/1996	Gross, et al.	604/140	
15.		5,582,591	12/10/1996	Cheikh	604/51	
16.		5,591,139	01/07/1997	Lin, et al.	604/264	
17.		5,801,057	09/01/1998	Smart, et al	436/68	
18.		5,820,622	10/13/1998	Gross, et al.	604/890.1	
19.		5,848,990	12/15/1998	Cirelli, et al.	604/136	
20.		5,848,991	12/15/1998	Gross, et al.	604/140	
21.	CA	5,876,582	03/02/1999	Frazier	205/122	

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

ATTORNEY DOCKET NO.

SERIAL NO.

6794S-000019/US

09/897,801

APPLICANT

Pinkerton, Thomas C.

FILING DATE

GROUP

June 29, 2001

1615

**PATENT AND TRADEMARK OFFICE**  
**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 2 of 6

**U.S. PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
22.	GA	5,879,326	03/09/1999	Godshall, et al.	604/51	
23.		5,928,207	07/27/1999	Pisano, et al.	604/272	
24.		5,957,895	09/28/1999	Sage, et al.	604/181	
25.		5,997,501	12/07/1999	Gross, et al.	604/65	
26.		6,056,716	05/02/2000	D'Antonio, et al.	604/68	
27.		6,099,504	08/08/2000	Gross, et al.	604/140	
28.		6,319,224 B1	11/20/2001	Stout, et al.	604/68	
29.		6,334,856 B1	01/01/2002	Allen, et al.	604/191	
30.	GA	6,346,095 B1	02/12/2002	Gross, et al.	604/272	
31.	GA	09/606909	—	Pettis, et al.	604/28	06/29/2000

**FOREIGN PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
32.	GA	CA 2,349,431	05/25/2000	Canada	<del>A61K 39/00</del>		
33.		EP 0 429 842 B1	08/28/1996	Europe EPO	<del>A61N 1/30</del>		
34.		EP 1 086 718 A1	03/28/2001	Europe EPO	<del>A61M 37/00</del>		
35.		EP 1 086 719 A1	03/28/2001	Europe EPO	<del>A61M 37/00</del>		
36.		EP 1 088 642 A1	04/04/2001	Europe EPO	<del>B29C 45/37</del>		
37.		EP 1 092 444 A1	04/18/2000	Europe EPO	<del>A61M 5/46</del>		
38.	GA	WO 94/23777	10/27/1994	PCT WIPO	<del>A61M 5/42</del>		

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

ATTORNEY DOCKET NO.

SERIAL NO.

6794S-000019/US

09/897,801

APPLICANT

Pinkerton, Thomas C.

FILING DATE

GROUP

June 29, 2001

1615

PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 3 of 6

## FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
39.	CA	WO 96/17648	06/13/1996	PCT <i>WIPO</i>	A61N 1/30		
40.		WO 96/37155	11/28/1996	PCT <i>WIPO</i>	A61B 17/20		
41.		WO 96/37256	11/28/1996	PCT <i>WIPO</i>	A61N 1/30		
42.		WO 97/21457	06/19/1997	PCT <i>WIPO</i>	A61M 5/20		
43.		WO 99/43350	09/02/1999	PCT <i>WIPO</i>	A61K 39/39		
44.		WO 99/64580	12/16/1999	PCT <i>WIPO</i>	G12N 15/00		
45.		WO 00/09186	02/24/2000	PCT <i>WIPO</i>	A61M 5/30		
46.		WO 00/67647	11/16/2000	PCT <i>WIPO</i>	A61B 17/22		
47.		WO 00/74763 A2	12/14/2000	PCT <i>WIPO</i>	A61M 37/00		
48.		WO 01/13903 A2	03/01/2001	PCT <i>WIPO</i>	A61K 31/00		
49.		WO 01/37882 A2	05/31/2001	PCT <i>WIPO</i>	A61K 49/00		
50.		WO 01/52854 A1	07/26/2001	PCT <i>WIPO</i>	A61K 31/5355		
51.	CA	WO 02/11669 A2	02/14/2002	PCT <i>WIPO</i>	A61K		

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
52.	CA	Agrawal, et al.; <i>Pharmacokinetics, Biodistribution And Stability Of Oligodeoxynucleotides Phosphorothioates In Mice</i> ; Proc. Natl. Acad. Sci. USA 88:7595-7599 (1991)
53.	CA	Autret, et al.; <i>Comparison Of Pharmacokinetics And Tolerance Of Calcitonine Administered By Intradermal Or Subcutaneous Route</i> ; Fundamental Clinical Pharmacology; 3(2):170-171 (1989)

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

ATTORNEY DOCKET NO.

SERIAL NO.

6794S-000019/US

09/897,801

APPLICANT

Pinkerton, Thomas C.

FILING DATE

GROUP

June 29, 2001

1615

PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 4 of 6

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
54.	CA	Benoni, et al.; <i>Distribution Of Ceftazidime In Ascitic Fluid; Antimicrobial Agents and Chemotherapy</i> ; 25(6): 760-763, (1984)
55.		Bocci, et al.; <i>The Lymphatic Route. IV. Pharmacokinetics Of Human Recombinant Interferon <math>\alpha_2</math> And Natural Interferon <math>\beta</math> Administered Intradermally In Rabbits; International Journal of Pharmaceuticals</i> ; 32:103-110 (1986)
56.		Bressolle, et al.; <i>A Weibull Distribution Model for Intradermal Administration of Ceftazidime; Journal of Pharmaceutical Sciences</i> ; 82(11): 1175-1178 (1993)
57.		Bronaugh, et al.; <i>Methods For In Vitro Percutaneous Absorption Studies II. Animal Models For Human Skin; Toxicology and Applied Pharmacology</i> ; 62:481-488 (1982)
58.		Burkoth, et al.; <i>Transdermal And Transmucosal Powdered Drug Delivery; Critical Reviews in Therapeutic Drug Carrier Systems</i> ; 16(4):331-384 (1999)
59.		Callen, Jeffrey P., M.D.; <i>Intralesional Corticosteroids; Therapy</i> 4(2): 149-151 (1981)
60.		Clinical Pharmacology Skin Disease (David R. Bickers, MD, et al. eds., Churchill Livingstone, 1984) pp. 57-90
61.		Corbo, et al.; <i>Transdermal Controlled Delivery Of Propranolol From A Multilaminate Adhesive Device; Pharmaceutical Research</i> ; 6(9):753-758, (1989)
62.		Cossum, et al.; <i>Disposition Of The <math>^{14}\text{C}</math>-Labeled Phosphorothioate Oligonucleotide ISIS 2105 After Intravenous Administration To Rats; Journal of Pharmacology and Experimental Therapeutics</i> ; 267(3):1181-1190 (1993)
63.		Cossum, et al.; <i>Pharmacokinetics Of A <math>^{14}\text{C}</math>-Labeled Phosphorothioate Oligonucleotide, ISIS 2105, After Intradermal Administration In Rats; Journal of Pharmacology and Experimental Therapeutics</i> ; 269(1):89-94 (1994)
64.		Crooke, et al.; <i>A Pharmacokinetic Evaluation Of <math>^{14}\text{C}</math>-Labeled Afovirsen Sodium In Patients With Genital Warts; Clinical Pharmacology and Therapeutics</i> ; 56(6):641-646 (1994)
65.	CA	Firooz, et al., <i>Benefits And Risks Of Intralesional Corticosteroid Injection In The Treatment Of Dermatological Diseases; Clinical and Experimental Dermatology</i> ; 20:363-370 (1995)

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

ATTORNEY DOCKET NO.

SERIAL NO.

6794S-000019/US

09/897,801

APPLICANT

Pinkerton, Thomas C.

FILING DATE

GROUP

June 29, 2001

1615

PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 5 of 6

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
66.	CA	Goodarzi, et al.; <i>Organ Distribution And Stability Of Phosphorothioated Olgodeoxyribonucleotides In Mice</i> ; <u>Biopharmaceutics and Drug Disposition</u> ; 13:221-227 (1992)
67.		Haynes, et al.; <i>Ultra-Long-Duration Local Anesthesia Produced By Injection Of Lecithin-Coated Methoxyflurane Microdroplets</i> ; <u>Anesthesiology</u> ; 63:490-499 (1985)
68.		Henry, et al.; <i>Microfabricated Microneedles: A Novel Approach To Transdermal Drug Delivery</i> ; <u>Journal of Pharmaceutical Sciences</u> ; 87(8):922-925 (1998)
69.		Jakobson, et al.; <i>Variation In The Blood Concentration Of 1,1,2-Trichloroethane By Percutaneous Absorption And Other Routes Of Administration In The Guinea Pig</i> ; <u>Acta Pharmacol. Et Toxicol.</u> ; 41:497-506 (1977)
70.		Jarratt, et al.; <i>The Effects Of Intradermal Steroids On The Pituitary-Adrenal Axis And The Skin</i> ; <u>Journal of Investigative Dermatology</u> ; 62:463-466 (1974)
71.		Kirkpatrick, et al.; <i>Local Anesthetic Efficacy Of Methoxyflurane Microdroplets In Man</i> ; <u>Anesthesiology</u> ; 67(3A):A254 (1987)
72.		Leroy, et al.; <i>Pharmacokinetics Of Ceftazidime In Normal And Uremic Subjects</i> ; <u>Antimicrobial Agents And Chemotherapy</u> ; 25(5):638-642 (1984)
73.		McAllister, et al.; <i>Three-Dimensional Hollow Microneedle And Microtube Arrays</i> ; 10 <sup>th</sup> International Conference on Solid-State Sensors and Actuators – Transducers '99; 2:1098-1101 (1999)
74.		McAllister, et al.; <i>Solid And Hollow Microneedles For Transdermal Protein Delivery</i> ; <u>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</u> ; 26:192-193 (1999)
75.		McGugan, et al.; <i>Adrenal Suppression From Intradermal Triamcinolone</i> ; <u>Journal of Investigative Dermatology</u> ; 40:271-272 (1963)
76.		Prausnitz, et al.; <i>Microfabricated Needles For Transdermal Protein Delivery</i> ; present at Bioengineering Applications of Microfabrication, November 5, 1999
77.		Scott, et al.; <i>Toxicity Of Interferon</i> ; <u>British Medical Journal</u> ; 282:1345-1348 (1981)
78.	AS	Supersaxo, et al.; <i>Recombinant Human Interferon Alpha-2a: Delivery To Lymphoid Tissue By Selected Modes Of Application</i> ; <u>Pharmaceutical Research</u> ; 5(8):472-476 (1988)

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE**  
**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 6 of 6

ATTORNEY DOCKET NO.

6794S-000019/US

SERIAL NO.

09/897,801

APPLICANT

Pinkerton, Thomas C.





FILING DATE

June 29, 2001

GROUP

1615

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)**

Ref. Desig.	Examiner's Initials	
79.		Sutherst, J.R.; <i>Treatment of Pruritus Vulvae By Multiple Intradermal Injections of Alcohol. A Double-Blind Study</i> ; <u>British Journal of Obstetrics and Gynaecology</u> ; 86:371-373 (1979)
80.		Ward, et al.; <i>Pruritus Vulvae: Treatment By Multiple Intradermal Alcohol Injections</i> ; <u>British Journal of Dermatology</u> ; 93:201-204 (1975)
81.		Wu, et al.; <i>Pharmacokinetics Of Methoxyflurane After Its Intra-Dermal Injection As Lecithin-Coated Microdroplets</i> ; <u>Journal of Controlled Release</u> 9:1-2 (1989)
82.		Zaynoun, et al.; <i>The Effect Of Intracutaneous Glucocorticoids On Plasma Cortisol Levels</i> ; <u>British Journal of Dermatology</u> ; 88:151-156 (1973)

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.